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Summary
Background New anti-tuberculosis regimens that are shorter, simpler, and less toxic than those that are currently 
available are needed as part of the global effort to address the tuberculosis epidemic. We aimed to investigate the 
bactericidal activity and safety profile of combinations of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in 
the first 8 weeks of treatment of pulmonary tuberculosis.
Methods In this multicentre, open-label, partially randomised, phase 2b trial, we prospectively recruited patients with 
drug-susceptible or rifampicin-resistant pulmonary tuberculosis from seven sites in South Africa, two in Tanzania, 
and one in Uganda. Patients aged 18 years or older with sputum smear grade 1+ or higher were eligible for enrolment, 
and a molecular assay (GeneXpert or MTBDRplus) was used to confirm the diagnosis of tuberculosis and to distinguish 
between drug-susceptible and rifampicin-resistant tuberculosis. Patients who were HIV positive with a baseline 
CD4 cell count of less than 100 cells per uL were excluded. Patients with drug-susceptible tuberculosis were randomly 
assigned (1:1:1) using numbered treatment packs with sequential allocation by the pharmacist to receive 56 days of 
treatment with standard tuberculosis therapy (oral isoniazid, rifampicin, pyrazinamide, and ethambutol; HRZE), or 
pretomanid (oral 200 mg daily) and pyrazinamide (oral 1500 mg daily) with either oral bedaquiline 400 mg daily on 
days 1–14 then 200 mg three times per week (BloadPaZ) or oral bedaquiline 200 mg daily (B200PaZ). Patients with 
rifampicin-resistant tuberculosis received 56 days of the B200PaZ regimen plus moxifloxacin 400 mg daily (BPaMZ). 
All treatment groups were open label, and randomisation was not stratified. Patients, trial investigators and staff, 
pharmacists or dispensers, laboratory staff (with the exception of the mycobacteriology laboratory staff), sponsor staff, 
and applicable contract research organisations were not masked. The primary efficacy outcome was daily percentage 
change in time to sputum culture positivity (TTP) in liquid medium over days 0–56 in the drug-susceptible 
tuberculosis population, based on non-linear mixed-effects regression modelling of log10(TTP) over time. The efficacy 
analysis population contained patients who received at least one dose of medication and who had efficacy data 
available and had no major protocol violations. The safety population contained patients who received at least one 
dose of medication. This study is registered with ClinicalTrials.gov, NCT02193776, and all patients have completed 
follow-up.
Findings Between Oct 24, 2014, and Dec 15, 2015, we enrolled 180 patients with drug-susceptible tuberculosis (59 were 
randomly assigned to BloadPaZ, 60 to B200PaZ, and 61 to HRZE) and 60 patients with rifampicin-resistant tuberculosis. 
57 patients in the BloadPaZ group, 56 in the B200PaZ group, and 59 in the HRZE group were included in the primary 
analysis. B200PaZ produced the highest daily percentage change in TTP (5·17% [95% Bayesian credibility interval 
4·61–5·77]), followed by BloadPaZ (4·87% [4·31–5·47]) and HRZE group (4·04% [3·67–4·42]). The bactericidal activity 
in B200PaZ and BloadPaZ groups versus that in the HRZE group was significantly different. Higher proportions of 
patients in the BloadPaZ (six [10%] of 59) and B200PaZ (five [8%] of 60) groups discontinued the study drug than in the 
HRZE group (two [3%] of 61) because of adverse events. Liver enzyme elevations were the most common grade 3 or 
4 adverse events and resulted in the withdrawal of ten patients (five [8%] in the BloadPaZ group, three [5%] in the 
B200PaZ group, and two [3%] in the HRZE group). Serious treatment-related adverse events affected two (3%) patients 
in the BloadPaZ group and one (2%) patient in the HRZE group. Seven (4%) patients with drug-susceptible tuberculosis 
died and four (7%) patients with rifampicin-resistant tuberculosis died. None of the deaths were considered to be 
related to treatment. 
Interpretation B200PaZ is a promising regimen to treat patients with drug-susceptible tuberculosis. The bactericidal 
activity of both these regimens suggests that they have the potential to shorten treatment, and the simplified dosing 
schedule of B200PaZ could improve treatment adherence in the field. However, these findings must be investigated 
further in a phase 3 trial assessing treatment outcomes.
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Introduction
Tuberculosis is the leading cause of death globally from 
an infectious disease.1 The treatment for drug-susceptible 
tuberculosis has not changed for two decades and 
continues to be based on isoniazid and rifampicin given 
for at least 6 months, supplemented by pyrazinamide 
and ethambutol given in the first 2 months (HRZE).2 
The length of therapy and associated logistical challenges, 
along with recognised treatment-associated toxicity, 
result in favourable outcomes in approximately 80% of 
people with drug-susceptible tuberculosis in real-world 
settings.1
The HIV epidemic and the emergence of multidrug-
resistant tuberculosis continue to act as major drivers of 
the tuberculosis epidemic.3 Patients with tuberculosis 
and HIV coinfection are at greater risk of treatment 
failure4,5 and higher treatment-related toxicity from 
tuberculosis medication than those with tuberculosis 
only, with the potential for overlapping toxicity from 
antiretroviral therapy (ART).6,7 Multidrug-resistant 
tuberculosis is a disease with strains resistant to both 
rifampicin and isoniazid, and a 2018 communication8 
from WHO recommends treating both multidrug-resist-
ant and rifampicin-resistant tuberculosis with either a 
20–24-month all-oral regimen or a shorter 9–11-month 
regimen for patients with confirmed fluoroquinolone 
and aminoglycoside sensitivity. The short regimen still 
requires a minimum 4 months of treatment in an 
intensive phase using an aminoglycoside (amikacin) with 
the consequent risk of ototoxicity, renal toxicity, and 
logistical challenges of parenteral drug administration. 
The 20–24-month oral regimen consists of five drugs: 
levofloxacin or moxifloxacin, bedaquiline, linezolid, 
clofazimine, and cycloserine or terizidone. Further drugs 
can be added from an approved list to complete the 
regimen if any of these drugs are contraindicated.
Much shorter, efficacious, and better-tolerated oral 
regimens than are currently available are required to tackle 
the ongoing epidemic in both drug-susceptible tuberculosis 
and multidrug-resistant and rifampicin-resistant tuber-
culosis. Fluoroquinolones have been studied previously for 
the first 2 months of anti tuberculosis treatment as 
substitutions for one of the standard first-line therapy 
drugs.9–12 Combination therapy of moxifloxacin with 
pretomanid and pyrazinamide was studied during an 
8-week phase 2b study.13 Bedaquiline has been studied as 
an adjuvant therapy to the standard five-drug second-line 
antituberculosis regimen in a 2-month phase 2b trial.14 A 
novel regimen of beda quiline, pretomanid, pyrazinamide, 
and clofazimine was previously studied in a phase 2a trial.15 
Research in context
Evidence before this study
We searched PubMed for clinical trials published between 
Jan 1, 1970, and Dec 31, 2015, studying tuberculosis drug 
regimens reporting sputum culture results during the first 
2 months of therapy. PubMed search terms used included 
“pulmonary tuberculosis” AND “antituberculosis” AND 
“two-month sputum culture-negativity” OR “sputum culture-
positivity” AND “serial mycobacterial culture” AND 
“fluoroquinolones” AND “bedaquiline” AND “relapse rates”. 
Fluoroquinolones have been studied in both phase 2 and phase 
3 studies of antituberculosis therapy previously as substitutions 
for one of the standard first-line therapy drugs. Phase 2b 
studies have been done of moxifloxacin, pretomanid, and 
pyrazinamide in different combinations, and of bedaquiline as 
adjuvant therapy to standard five-drug second-line tuberculous 
treatment. A regimen comprising bedaquiline, pretomanid, 
and clofazimine was previously studied in a phase 2a trial. 
Added value of this study
This trial was the first phase 2b study investigating the efficacy 
and safety of the combination therapy of bedaquiline, 
pretomanid, and pyrazinamide, with or without moxifloxacin in 
patients with drug-susceptible and multidrug-resistant 
tuberculosis. The combination therapy of bedaquiline, 
pretomanid, and pyrazinamide has not been investigated 
elsewhere except in a phase 2a study sponsored by TB Alliance. 
This phase 2b study was also the first to investigate 
two different dosing schedules of bedaquiline.
Implications of all the available evidence
In patients with tuberculosis, the combination therapy of 
bedaquiline, pretomanid, and pyrazinamide, with or without 
moxifloxacin, had superior bactericidal activity during the first 
8 weeks of treatment compared with standard treatment of 
isoniazid, rifampicin, pyrazinamide, and ethambutol. 
Simplified, once-daily dosing for bedaquiline showed 
bactericidal activity similar to the established dosing schedule. 
Bedaquiline, pretomanid, and pyrazinamide plus moxifloxacin 
and bedaquiline, pretomanid, and pyrazinamide hold promise 
for outcomes superior to the standard therapy for multidrug-
resistant tuberculosis and drug-susceptible tuberculosis, 
respectively. These regimens can now be taken forward to 
phase 3 studies (to be assessed for improvement in tuberculosis 
treatment outcomes as measured by shortening of tuberculosis 
treatment duration and simplification of regimens for drug-
susceptible and multidrug-resistant tuberculosis).
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We aimed to determine the safety and efficacy of 
8-week treatment with the combination therapy of 
bedaquiline, pretomanid, and pyrazinamide (BPaZ) 
compared with standard tuberculosis therapy in patients 
with newly diagnosed drug-susceptible tuberculosis 
using two different dosing strategies for bedaquiline. We 
also assessed the response in patients with rifampicin-
resistant tuberculosis over 8 weeks with the addition 
of moxifloxacin to a BPaZ regimen (BPaMZ), to 
compensate for possible pyrazina mide resistance in 
these patients.
Methods
Study design
NC-005 was a multicentre, open-label, partially rand-
omised, phase 2b trial done in seven sites in South 
Africa, two sites in Tanzania, and one site in Uganda. All 
sites adopted outpatient management, with the exception 
of the site in Uganda, where patients with rifampicin-
resistant tuberculosis were admitted for the first week 
(approximately) of treatment, in keeping with existing 
local practice for patients with rifampicin-resistant 
tuberculosis.
The study was approved by the applicable national and 
local ethics committees at the different sites. A list of the 
ethics committees can be found in the appendix (pp 2–3). 
The use of pretomanid in drug-susceptible tuberculosis 
was ethically justified based on previous experience with 
the drug in phase 2 and 3 trials, and in light of the 
acknowledged need for shorter treatment regimens in 
drug-susceptible disease that are not impaired in the 
presence of isoniazid monoresistance. The protocol is 
available online. 
Patients
Patients aged 18 years or older with positive direct sputum 
microscopy for acid-fast bacilli, grade 1+ or higher on the 
WHO/International Union Against Tuberculosis and 
Lung Disease scale,16 were eligible for inclusion in the 
study. The full list of inclusion and exclusion criteria can 
be found in the appendix (pp 4–6). Patients included in 
the drug-susceptible tuber culosis cohort had strains 
susceptible to isoniazid and rifampicin and those 
included in the rifampicin-resistant tuber culosis cohort 
had strains resistant to rifampicin but sensitive to 
fluoroquinolones. 
A molecular assay was used for identification 
of Mycobac terium tuberculosis and drug susceptibility 
(GeneXpert [Cepheid, Sunnyvale, CA, USA] or 
MTBDRplus [Hain Lifescience, Nehren, Germany]) to 
confirm the diagnosis of tuberculosis, and to distinguish 
between drug-susceptible tuberculosis and rifampicin-
resistant tuberculosis; cases of rifampicin-resis tant tuber-
culosis were further tested for fluoroquinolone resistance 
using a molecular platform (MTBDRsl [Hain Lifescience]). 
MTBDRplus was used to detect isoniazid and rifampicin 
resistance, where available.
Patients with HIV were eligible if their CD4 cell count 
was higher than 100 cells per μL at baseline. All patients 
had their baseline CD4 cell count checked because it was 
an exclusion criterion; however, viral load was not routinely 
checked. The site doctor was responsible for ART of HIV-
positive patients in the study, and ART use was encouraged 
for all HIV-positive patients. Permitted ART regimens in 
the study are presented in the exclusion criteria in the 
appendix (p 5). However, if the patient was not already 
taking a permitted ART regimen, a 2-week interval was 
required after starting trial medication and initiating ART 
to reduce the risk of immune reconstitution inflam matory 
synd rome. The protocol did not require that HIV-positive 
patients were initiated on ART, and the final judgment 
was left to the site doctor managing the patient.
Patients were excluded from the study if there was 
evidence of clinically significant extrathoracic tuber-
culosis, which would have been clinically evaluated by the 
site doctor. Other exclusion criteria included risks for 
cardiac arrhythmia (eg, QTc interval >450 ms), alanine 
aminotransferase (ALT) or aspartate aminotransferase 
(AST) concentrations of 3 × upper limit of normal (ULN) 
or more, alkaline phosphatase concentration of more than 
8 × ULN, and total bilirubin concentration of 2 × ULN or 
more at baseline. All patients provided written or oral, 
witnessed, informed consent before any screening 
procedures were carried out. A patient information sheet 
was provided and translated into appropriate languages.
Randomisation and masking
Patients with drug-susceptible tuberculosis were randomly 
assigned (1:1:1) to receive one of three treatment regimens: 
two experimental BPaZ regimens or standard tuberculosis 
therapy as a control. The randomisation list was generated 
by people not directly involved with the trial. All treatment 
groups were open label. Patients, trial investigators and 
staff, pharmacists or dispensers, laboratory staff (with 
the exception of the mycobacteriology laboratory staff), 
sponsor staff, and applicable contract research organ-
isations were not masked. 
A treatment pack was available for each patient and was 
identified by a treatment number. To ensure that there 
was no bias in treatment assignment, the randomisation 
list was retained by the pharmacist or registered dispenser. 
The person responsible for overseeing the random 
assignment for the drug-susceptible tuberculosis cohort 
and allocation for the rifampicin-resistant cohort was not 
directly involved in patient care.
At the time of assignment, the trial centre requested the 
pharmacist or registered dispenser to assign a study drug 
treatment pack to the patient depending on their drug 
susceptibility or multidrug-resistant tuberculosis status. 
The pharmacist or regis tered dispenser accordingly 
assigned the patient the next available applicable treatment 
pack, sequen tially starting from the lowest unused 
treatment number. A cohort of patients with rifampicin-
resistant tuber culosis was allo cated to receive BPaMZ. 
For the protocol see 
https://www.tballiance.org/
portfolio/trial/5097
See Online for appendix
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Procedures
Patients with drug-susceptible tuberculosis in the 
BloadPaZ and B200PaZ groups received pretomanid oral 
200 mg and pyrazinamide oral 1500 mg once daily on 
days 1–56 with bedaquiline. Patients in the BloadPaZ group 
received oral bedaquiline 400 mg once daily for the first 
14 days, and oral 200 mg three times per week for the 
remaining days; those in the B200PaZ group received oral 
bedaquiline 200 mg once daily throughout the 8 weeks of 
therapy. Patients in the control group were prescribed 
fixed-dose combination pills containing isoniazid, 
rifampicin, pyraz in amide, and ethambutol (HRZE) on 
the basis of their weight at baseline (HRZE tablets 
[MacLeods Pharma ceuticals, Mumbai, India]). 
Patients with rifampicin-resis tant tuberculosis were 
allocated to receive treatment with oral bedaquiline 
200 mg, oral pretomanid 200 mg, oral pyrazin amide 
1500 mg, and oral moxifloxacin 400 mg (BPaMZ) daily for 
8 weeks. Adherence to outpatient treatment was based on 
patient reporting; site staff recorded adherence if the 
patient was treated in hospital. For details on drug dosing, 
see the appendix (p 7).
Overnight sputum samples were collected from patients 
before randomisation (day –1 and –2) and days 1, 3, 7, 14, 
21, 28, 35, 42, 49 and 56 after randomisation. Colony-
forming unit (CFU) counts on solid media and time to 
sputum culture positivity (TTP) in Mycobacterial Growth 
Indicator Tube (MGIT; BD, Franklin Lakes, NJ, USA) on 
Figure 1: Trial profile
Full listings of the reasons for screening failure are available in the appendix (p 7). AFB=acid-fast bacilli. ALT=alanine aminotransferase. AST=aspartate aminotransferase. BloadPaZ=bedaquiline (loading 
dose), pretomanid, and pyrazinamide. B200PaZ=bedaquiline (daily dose), pretomanid, and pyrazinamide. BPaMZ=bedaquiline (daily dose), pretomanid, and pyrazinamide plus moxifloxacin. 
HRZE=isoniazid, rifampicin, pyrazinamide, and ethambutol. *Primary reason for withdrawal during treatment.
59 assigned to BloadPaZ
51 completed treatment (54 completed
 day 70 follow-up and 52 completed
 day 140 follow-up)
57 included in efficacy analysis population
2 excluded
 2 pyrazinamide resistant
8 withdrawn* during treatment
5 adverse events or specific
toxicity
1 withdrew consent
1 died
1 investigator and funder 
 decision
60 assigned to B200PaZ 61 assigned to HRZE 
60 patients with rifampicin-resistant 
tuberculosis assigned to BPaMZ
(safety analysis population)
180 patients with drug-susceptible 
tuberculosis randomly assigned
 (safety analysis population)
2 withdrawn* during treatment
2 adverse events or specific
toxicity
240 enrolled
469 patients screened
229 excluded
49 with no smear positive test or positive molecular test
30 with AFB <1+ or indeterminate
25 with CD4 cell count <100 cells per µL
25 with QTc interval duration >450 ms
12 with alcohol or drug use
9 withdrew consent
6 with ALT or AST ≥3·0 × ULN
73 other reasons
53 completed treatment (56 completed
 day 70 follow-up and 52 completed
 day 140 follow-up)
56 included in efficacy analysis population 59 included in efficacy analysis population
4 excluded 
 3 pyrazinamide resistant
 1 no efficacy data
7 withdrawn* during treatment
5 adverse events or specific
toxicity
1 investigator and funder 
 decision
1 failure to comply with
 protocol
59 completed treatment (60 completed
 day 70 follow-up and 58 completed
 day 140 follow-up)
2 excluded
 2 pyrazinamide resistant
2 withdrawn* during treatment
2 adverse events or specific
toxicity
38 included in efficacy analysis population
58 completed treatment (60 completed 
 day 70 follow-up  and 58 completed 
 day 140 follow-up)
22 excluded
 22 pyrazinamide resistant 
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liquid media (ie, the time it takes for a sputum culture to 
grow positive for tuberculosis [expressed in hours]) were 
measured on all sputum samples. TTP was specified as 
the primary readout in all analyses.
Patients enrolled in the study attended scheduled visits 
at each site between day 1 and day 140 (see appendix p 8 
for full visit schedule). Electrocardiograms (ECGs) were 
carried out routinely during screening, and on days 1, 15, 
29, 43, 57, and 70. All patients were referred to the 
national tuberculosis programme of the country where 
they were being treated for further treatment after 
finishing their study-allocated treatment, but the survival 
status of patients was checked by phone calls at months 
8, 14, 20, and 26. Full blood count, clinical chemistry, and 
liver biochemical tests were done at screening and days 
1, 8, 15, 22, 29, 36, 43, 50, 57 and 70.
Adverse events were classified according to the 
Division of Microbiology and Infectious Disease Adult 
Toxicity Table17 as a numerical score for assessing the 
severity of the event. The site doctor was to actively 
enquire about any adverse medical events that the 
patient had experienced at every visit (including 
assessing whether previously recorded events had 
worsened or improved) and to record event severity, 
date of onset and stop date (if applicable), action taken 
with study medication in response to the event, and 
relationship to study medication. 
The attribution of relatedness was ultimately left to the 
clinical judgment of the site doctor with guidance provided 
to assess the event as one of “not related”, “unlikely 
related”, “possibly related”, “probably related”, or “definitely 
related”, and in the final dataset any event assessed as 
possibly, probably, or definitely related was considered 
“related”. 
An independent data safety man age ment committee 
met twice during the study to review unblinded aggregate 
data and provided feedback to the sponsor. On both of 
these occasions, the recommendation was to continue 
without any change to the trial design. 
Outcomes
The primary efficacy outcome was the daily percentage 
change in TTP over days 0–56 in the drug-susceptible 
tuberculosis population, based on non-linear mixed-
effects regression modelling of log10(TTP) over time. For 
all efficacy outcomes, the primary analysis was based on 
cultures of overnight sputum samples.
A secondary efficacy endpoint was the time to sputum 
culture conversion in solid and liquid media in patients 
with drug-susceptible tuberculosis and in those with 
rifampicin-resistant tuberculosis. Other secondary efficacy 
endpoints included the daily rate of decline in log10 (CFU) 
count over days 0–56 and a subgroup analysis comparing 
the bact ericidal activity among pyrazinamide-resistant 
versus pyrazinamide-susceptible inf ec tions in patients 
with rifampicin-resistant tuber culosis, and among HIV-
positive and HIV-negative patients (see appendix p 10 for 
the full list of secondary endpoints). The safety analysis 
included the incidence of treatment emergent adverse 
events and abnormal labor atory tests for each treatment 
Patients with drug-susceptible tuberculosis Patients with 
rifampicin-resistant 
tuberculosis  
(BPaMZ group 
[n=60])
BloadPaZ group 
(n=59)
B200PaZ group 
(n=60)
HRZE group 
(n=61)
Age*, years 35·1 (13·0) 33·9 (10·5) 33·3 (8·6) 34·0 (12·7)
Sex
Female 14 (24%) 12 (20%) 15 (25%) 17 (28%)
Male 45 (76%) 48 (80%) 46 (75%) 43 (72%)
Race
Black or African American 46 (78%) 49 (82%) 49 (80%) 53 (88%)
Native Hawaiian or other Pacific 
Islander
0 0 0 1 (2%)
White 0 0 0 1 (2%)
Mixed race 13 (22%) 11 (18%) 12 (18%) 5 (8%)
Site
TASK, Cape Town 11 (19%) 12 (20%) 13 (21%) 10 (17%)
UCTLI, Cape Town 13 (22%) 13 (22%) 13 (21%) 0
CHIVRU, Helen Joseph 5 (9%) 5 (8%) 5 (8%) 0
Aurum Institute, Tembisa 5 (9%) 5 (8%) 4 (7%) 0
Tshepong, Klerksdorp 0 0 0 25 (42%)
Ifakara, Bagamoyo 10 (17%) 10 (17%) 11 (18%) 0
Mbeya Research Centre, Mbeya 11 (19%) 11 (18%) 10 (16%) 0
UWCHIVRU, Johannesburg 0 0 0 2 (3%)
THINK, Durban 4 (7%) 4 (7%) 5 (8%) 0
Case Western, Kampala 0 0 0 23 (38%)
Weight, kg 56·1 (10·8) 54·4 (9·1) 52·7 (8·8) 50·8 (8·4)
HIV status
Positive 8 (14%) 10 (17%) 10 (16%) 25 (42%)
CD4 cell count 456·5 (135·1) 264·7 (89·6) 620·6 (307·4) 400·3 (220·5)
Negative 51 (86%) 50 (83%) 51 (84%) 35 (58%)
Antiretroviral therapy at randomisation
Yes 0 1 (10%) 0 16 (64%)
No 8 (100%) 9 (90%) 10 (100%) 9 (36%)
Pyrazinamide susceptibility
Susceptible 57 (97%) 57 (95%) 59 (97%) 38 (63%)
Resistant 2 (3%) 3 (5%) 2 (3%) 22 (37%)
Ethambutol susceptibility
Susceptible 54 (96%) 51 (93%) 57 (97%) 39 (78%)
Resistant 2 (4%) 4 (7%) 2 (3%) 11 (22%)
Not done 0 0 0 1 (2%)
Compliance to study drug
<80% 0 0 0 0
≥80% 59 (100%) 60 (100%) 61 (100%) 60 (100%)
Data are n (%) or mean (SD). BloadPaZ=bedaquiline (loading dose), pretomanid, and pyrazinamide. B200PaZ=bedaquiline 
(daily dose), pretomanid, and pyrazinamide. BPaMZ=bedaquiline (daily dose), pretomanid, and pyrazinamide plus 
moxifloxacin. CHIVRU=Clinical HIV Research Unit. HRZE=isoniazid, rifampicin, pyrazinamide, and ethambutol. 
UCTLI=University of Cape Town Lung Institute. UWCHIVRU=University of Witwatersrand Clinical HIV Research Unit. 
*Calculated relative to informed consent.
Table 1: Demographic and other baseline characteristics of the safety analysis population
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group. In addition, ECG findings, including QT and QTc 
intervals, for patients in each treatment group were also 
analysed.
Statistical analysis
For this study, the sample size calculation was based on 
an earlier study1 that reported mean rate constants from 
a non-linear mixed-effects regression model for the rate 
of decline in CFU count over 56 days of treatment. 
On the basis of a sample of 50 patients per treatment 
group (given a one-sided significance level of 2·5%), the 
statistical power to yield a significant difference between 
groups was 86% for second-phase (or terminal-phase) 
response.9,13 All statistical tests were two-sided with a 
significance level of 5%. We did no multiplicity 
adjustments for this study. Descriptive statistics included 
the number (%) of patients, mean (SD), and minimum, 
median (IQR), and maximum where applicable.
The safety analysis population contained patients who 
received at least one dose of study drug. The efficacy 
analysis population contained patients included in the 
safety analysis population for whom efficacy data were 
avail able and who had no major protocol violations that 
could affect the integrity of the data, such as those relating 
to eligibility criteria or ethics approvals. All analyses are 
presented without adjustment for base line covariates as 
randomisation was not stratified.
We estimated the bactericidal activity parameters by 
the fit of a Bayesian non-linear mixed-effects regression 
model to log10(TTP)18 and log10(CFU) count19,20 of all 
patients with drug-susceptible tuberculosis jointly. The 
bactericidal activity was characterised by the daily 
percentage change in time to positive signal, and the 
daily change in log(CFU) of overnight sputum samples. 
The posterior estimates and corresponding 95% 
Bayesian credibility intervals (BCIs) for the mean 
bactericidal activity characteristics are presented. We 
did pairwise comparisons of the B200PaZ and BloadPaZ 
groups against the HRZE group to investigate 
bactericidal activity of the experimental treatment 
groups. 
We did a Kaplan-Meier analysis to test the difference in 
the cumulative proportion of patients with drug-suscep-
tible tuber culosis who were culture negative, in solid and 
liquid media, at 8 weeks in the experimental treat ment 
groups versus the HRZE group. We compared the median 
time to culture conversion in the B200PaZ and BloadPaZ 
groups versus the HRZE group using the log-rank test. 
We calculated the corresponding hazard ratios for time 
to negative culture in liquid and solid culture using Cox 
proportional hazards regression modelling without the 
adjustment of covariates. Model assumptions were 
tested to ensure that there were no violations, and 
censoring occurred at 8 weeks or if the patient was 
withdrawn from the study. The proportion of patients 
within each category of adverse events was compared 
between treatments using the Freeman-Halton test in a 
post-hoc analysis. All analyses were done with SAS 
(version 9.4), OpenBUGS (version 3.1.3), and R (version 
3.0.2). This study is registered with ClinicalTrials.gov, 
NCT02193776.
Role of funding source
The funders of the study were involved in study design, 
data collection, data analysis, data interpretation, and 
writing of this report. Monitoring visits were carried 
out by the monitoring clinical research organisation 
appointed by TB Alliance. Monitoring took place 
according to the monitoring plan (see protocol). A risk-
based approach was followed with both on-site and 
remote monitoring at the intervals specified in the 
monitoring plan. Intervals depended on the stage of the 
study at the sites to ensure accurate data collection 
relating to both efficacy and safety findings. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
BloadPaZ group (n=57) B200PaZ group (n=56) HRZE group (n=59)
Daily percentage change in 
time to positive signal
4·87% (4·31–5·47) 5·17% (4·61–5·77) 4·04% (3·67–4·42)
Daily change in log(CFU) of 
overnight sputum samples
0·12 (0·11–0·14) 0·11 (0·10–0·12) 0·12 (0·11–0·13)
Data are posterior mean estimate (95% Bayesian credibility interval). The differences between the pairs of treatments 
BloadPaZ versus HRZE and B200PaZ versus HRZE were significant. BloadPaZ=bedaquiline (loading dose), pretomanid, and 
pyrazinamide. B200PaZ=bedaquiline (daily dose), pretomanid, and pyrazinamide. CFU=colony-forming unit. 
HRZE=isoniazid, rifampicin, pyrazinamide, and ethambutol. 
Table 2: Bactericidal activity among patients with drug-susceptible tuberculosis over days 0–56 in the 
efficacy analysis population
BloadPaZ group (n=57) B200PaZ group (n=56) HRZE group (n=59)
Percentage culture negative at day 56 of treatment (95% CI)
Liquid culture 67·4% (53·8–80·9) 76·1% (64·0–88·3)* 51·0% (36·6–65·4)
Solid culture 88·9% (79·8–97·9) 84·0% (73·9–94·1) 85·5% (75·7–95·3)
Liquid culture median (IQR) time 
to culture negative, days
49*(35 to not 
obtained)
49* (35–56) 56 (49 to not 
obtained)
BloadPaZ=bedaquiline (loading dose), pretomanid, and pyrazinamide. B200PaZ=bedaquiline (daily dose), pretomanid, and 
pyrazinamide. HRZE=isoniazid, rifampicin, pyrazinamide, and ethambutol. *Significantly different to the HRZE control; 
the median times were compared with the HRZE control using the log-rank test. 
Table 3: Cumulative percentage in patients with drug-susceptible tuberculosis with culture negative 
overnight sputum samples and the median time to sputum culture conversion in the efficacy analysis 
population
BloadPaZ group (n=57) B200PaZ group (n=56) HRZE group (n=59)
Liquid culture 34 (60%); 1·8 (1·1–2·9) 37 (65%); 2·0 (1·3–3·2) 25 (42%); 1 (ref)
Solid culture 46 (81%); 1·3 (0·9–1·8) 43 (75%); 1·1 (0·8–1·6) 45 (76%); 1 (ref)
Data are n (%); hazard ratio (95% CI). The hazard ratio of time to culture negative status for BloadPaZ versus HRZE, and 
B200PaZ versus HRZE was significantly higher than 1 in liquid culture. BloadPaZ=bedaquiline (loading dose), pretomanid, 
and pyrazinamide. B200PaZ=bedaquiline (daily dose), pretomanid, and pyrazinamide. HRZE=isoniazid, rifampicin, 
pyrazinamide, and ethambutol.
Table 4: Hazard ratios for culture negative status among patients with drug-susceptible tuberculosis 
according to treatment group versus control group in the efficacy analysis population
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Results
Between Oct 24, 2014, and Dec 15, 2015, 180 patients 
drug-susceptible tuberculosis were randomly assigned to 
the BloadPaZ (n=59), B200PaZ (n=60), or HRZE (n=61) 
groups (figure 1). 60 patients with rifampicin-resistant 
tuberculosis were assigned to the BPaMZ group. 
Concurrent isoniazid resistance was detected in 53 (88%) 
of 60 rifampicin-resistant tuberculosis isolates.
182 (76%) of 240 participants were men, 197 (82%) were 
of black African ethnicity, and 53 (22%) patients were 
HIV positive (table 1). All patients had an overall 
adherence to study drug regimen of at least 80% of 
prescribed doses (table 1).
57 patients in the BloadPaZ group, 56 in the B200PaZ 
group, and 59 in the HRZE group were included in the 
primary analysis. In the efficacy analysis, patients in the 
B200PaZ group showed the highest daily percentage 
change in TTP (5·17% [95% BCI 4·61–5·77]), followed by 
those in the BloadPaZ group (4·87% [4·31–5·47]) and those 
in the HRZE group (4·04% [3·67–4·42]; table 2). The 
differences in bactericidal activity of the B200PaZ and 
BloadPaZ groups versus the HRZE group were significant. 
Descriptive statistics of log(TTP) are presented in the 
appendix (pp 11–13).
In the prespecified secondary analysis, among the 
drug-susceptible tuberculosis treatment groups, B200PaZ 
showed the highest cumulative percentage of culture 
negativity in liquid culture, followed by BloadPaZ and 
HRZE (table 3; figure 2). In liquid culture, the 
corresponding HR of time to culture negative status for 
BloadPaZ versus HRZE and B200PaZ versus HRZE was 
significantly higher than 1 in liquid culture (table 4). 
In the prespecified secondary subgroup analysis in 
the BPaMZ group, the pyrazinamide-suscep tible 
rifampicin-resistant tuberculosis group showed the 
highest cumulative percentage of culture negativity in 
liquid culture medium, followed by the pyrazinamide-
resistant rifampicin-resistant tuberculosis group 
(table 5). 
Bactericidal activity was similar in both HIV-positive 
and HIV-negative patients receiving BPaMZ (appen dix 
p 14). In our post-hoc analysis, we found no significant 
differences between the drug-susceptible tuberculosis 
treatment groups in the inci dence of adverse events. The 
proportion of patients with drug-susceptible tuberculosis 
with peak ALT or AST of at least 5 × ULN was higher for 
the BloadPaZ (six [10%] of 59 patients) and B200PaZ (four 
[7%] of 60 patients) groups than for patients receiving 
HRZE (three [5%] of 61 patients; table 6). No QT or QTc 
intervals of 500 ms or more were reported during 
treatment in the drug-susceptible tuberculosis groups. 
13 patients with drug-susceptible tuberculosis were 
prematurely withdrawn from study drug administration 
due to adverse events: six (10%) of 59 patients receiving 
BloadPaZ, five (8%) of 60 patients receiving B200PaZ, and 
two (3%) of 61 patients receiving HRZE. Increases in 
ALT or AST resulted in treatment discontinuation for ten 
patients (five [8%] patients in the BloadPaZ group, three 
[5%] patients in the B200PaZ group, and two [3%] patients 
in the HRZE group).
Figure 2: Kaplan-Meier curves of time to liquid (A) and solid (B) media sputum 
culture conversion the efficacy analysis population
Patients censored at last available valid sample day if no sample was collected at 
day 56. (A) The difference between B200PaZ versus HRZE with respect to the 
cumulative probability of liquid media sputum culture conversion is significant. 
No other differences between treatment groups were significant. (B) No 
differences between treatment groups were significant with respect to the 
cumulative probability of solid media sputum culture conversion. p values 
calculated from a log-rank test for comparison of median time to liquid media 
sputum culture conversion. BloadPaZ=bedaquiline (loading dose), pretomanid, and 
pyrazinamide. B200PaZ=bedaquiline (daily dose), pretomanid, and pyrazinamide. 
BPaMZ=bedaquiline (daily dose), pretomanid, and pyrazinamide plus moxifloxacin. 
HR=hazard ratio. HRZE=isoniazid, rifampicin, pyrazinamide, and ethambutol.
B200PaZ vs HRZE: HR 1·1 (95% CI 0·8–1·6); p=0·48
BloadPaZ vs HRZE: HR 1·3 (95% CI 0·9–1·8); p=0·18
BPaMZ vs HRZE: HR 2·3 (95% CI 1·5–3·4); p=0·0002
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B200PaZ vs HRZE: HR 2·0 (95% CI 1·3–3·2); p=0
BloadPaZ vs HRZE: HR 1·8 (95% CI 1·1–2·9); p=0·016
BPaMZ vs HRZE: HR 3·3 (95% CI 2·1–5·2); p<0·0001
BloadPaZ
B200PaZ
HRZE
BPaMZ
Pyrazinamide-
susceptible 
rifampicin-resistant 
tuberculosis (n=38)
Pyrazinamide-
resistant 
rifampicin-resistant 
tuberculosis (n=22)
Percentage culture negative at day 56 of treatment (95% CI)
Liquid culture 96·0% (88·5–100·0) 79·8% (62·4–97·2)
Solid culture 100·0% (100·0–100·0) 95·0% (85·3–100·0)
Liquid culture median 
(IQR) time to culture 
negative, days
41 (35–56) 49 (34–56)
BPaMZ=bedaquiline (daily dose), pretomanid, and pyrazinamide plus 
moxifloxacin.
Table 5: Cumulative percentage in patients in the BPaMZ group with 
rifampicin-resistant tuberculosis and culture negative overnight 
sputum samples, and the median time to sputum culture conversion
Articles
8 www.thelancet.com/respiratory   Published online November 12, 2019   https://doi.org/10.1016/S2213-2600(19)30366-2
Seven (4%) people died over the course of the 2-month 
treatment period and 2-year follow-up period among the 
drug-susceptible tuberculosis cohort (two [3%] patients in 
the BloadPaZ group, three [5%] patients in the B200PaZ 
group, and two [3%] patients in the HRZE group). Three of 
these deaths occurred during treatment (one [2%] in the 
BloadPaZ group on day 5, one [2%] in the B200PaZ group on 
day 23, and one [2%] in the HRZE group on day 44). For 
these three patients, the cause of death was reported as 
pneumothorax for both of the BloadPaZ and B200PaZ deaths, 
and acute liver and renal failure for the patient receiving 
HRZE. None of the deaths were considered to be related 
to treatment. Serious treatment-related adverse events 
affected two (3%) patients in the BloadPaZ group and one 
(2%) patient in the HRZE group.
Three (5%) of 60 patients with rifampicin-resistant 
tuberculosis receiving BPaMZ had a peak ALT or AST of 
at least 5 × ULN, and two (3%) patients withdrew because 
of adverse events. For both of these patients, the 
withdrawal was due to elevated liver enzymes. No 
recorded QTc intervals of more than 500 ms were 
recorded among patients with rifampicin-resistant 
tuberculosis. Four (7%) people died in the BPaMZ 
group: two deaths were considered to be due to 
tuberculosis, one was due to cor pulmonale, and one 
was due to drowning. All deaths occurred after treatment 
and none was related to treatment. Serious treatment-
related adverse events affected two (3%) patients in the 
BPaMZ group.
More details on the incidence of treatment-emergent 
adverse events by treatment group (for both drug-
suscep tible tuberculosis and rifampicin-resistant 
tuberculosis), including treatment withdrawals and 
relatedness assess ments by the site doctors, can be 
found in the appendix (p 16). A full listing of deaths 
during the trial can also be found in the appendix (p 15).
Discussion
This study investigated the bactericidal activity and safety 
of three experimental pretomanid and bedaquiline-
containing regimens for the treatment of pulmonary 
tuberculosis. Both the bedaquiline-containing treatment 
groups for drug-susceptible tuberculosis demonstrated 
superior bactericidal activity over HRZE; this effect was 
maintained even when a simplified dosing schedule was 
used for bedaquiline. However, the highest gain in 
bactericidal activity at day 56 of treatment compared with 
HRZE was seen with BPaMZ used to treat pyrazinamide-
susceptible rifampicin-resistant tuberculosis. The safety 
signal was similar for patients taking BPaMZ and HRZE, 
although more events were seen for patients taking the 
other two experimental regimens than for those receiving 
HRZE.
The BPaMZ regimen used to treat rifampicin-resistant 
tuberculosis showed superior bactericidal activity 
compared with HRZE in drug-susceptible tuberculosis. 
This regimen constitutes a much lower pill burden than 
the currently recommended WHO rifampicin-resistant 
tuberculosis treatment options and does not involve the 
use of injectable drugs. 
Globally, the proportion of successful outcomes from 
current rifampicin-resistant tuberculosis treatment is only 
54%.1 It is well recognised that this low proportion is due 
to a combination of the logistical challenges in delivering 
therapy over a long period of time, toxic effects from drugs 
(especially related to the injectable drugs), and use of less 
efficacious drugs than HRZE. BPaMZ could help to 
address these shortcomings as a simplified regimen that 
would be less demanding to deliver than even the 9-month 
WHO rifampicin-resistant tuberculosis regimen, pro-
vided its long-term efficacy with a well defined toxicity 
monitoring schedule can be shown in phase 3 trials. 
There is already evidence that rifampicin-resistant 
tuberculosis regimens containing bedaquiline can achieve 
success rates of 77% and reduce disease-associated 
mortality.21,22
The rapid fall in the rifampicin-resistant tuberculosis 
bacillary load seen in the time to culture negativity 
analysis in MGIT suggests a potent sterilising effect and 
Patients with drug-susceptible tuberculosis Patients with 
rifampicin-resistant 
tuberculosis 
(BPaMZ group 
[n=60])
BloadPaZ group 
(n=59)
B200PaZ group 
(n=60)
HRZE group 
(n=61)
p value
≥1 grade 3 treatment-
emergent adverse event
19 (32%) 17 (28%) 14 (23%) 0·53 13 (22%)
≥1 grade 4 treatment-
emergent adverse event
8 (14%) 7 (12%) 2 (3%) 0·11 1 (2%)
≥1 serious treatment-
emergent adverse event
4 (7%) 3 (5%) 4 (7%) 0·93 4 (7%)
≥1 serious liver-related 
treatment-emergent 
adverse event
2 (3%) 0 2 (3%) 0·47 2 (3%)
≥1 treatment-emergent 
adverse event leading to 
treatment 
discontinuation
6 (10%) 5 (8%) 2 (3%) 0·28 2 (3%)
Deaths during 
treatment/total deaths 
(%)
1/2 (50%) 1/3 (33%) 1/2 (50%) 1·0*; 0·90† 0/4 (0%)
Liver toxicity
ALT or AST ≥5 × ULN 6 (10%) 4 (7%) 3 (5%) 0·48 3 (5%)
ALT or AST ≥10 × ULN 3 (5%) 3 (5%) 1 (2%) 0·57 1 (2%)
ECG findings
≥60 ms increase in 
QTc interval from 
baseline
0 3 (5%) 1 (2%) 0·07 0
Data are n (%) unless otherwise stated. All patients who received at least dose of trial medication included in the analysis. 
ALT=alanine aminotransferase. AST=aspartate aminotransferase. BloadPaZ=bedaquiline (loading dose), pretomanid, and 
pyrazinamide. B200PaZ=bedaquiline (daily dose), pretomanid, and pyrazinamide. BPaMZ=bedaquiline (daily dose), 
pretomanid, and pyrazinamide plus moxifloxacin. ECG=electrocardiogram. HRZE=isoniazid, rifampicin, pyrazinamide, 
and ethambutol. ULN=upper limit of normal. *p value for deaths during treatment. †p value for total deaths.
Table 6: Adverse events in the safety analysis population
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also the potential for BPaMZ to shorten the duration of 
treatment for drug-susceptible tuberculosis. 
Another reason to support the use of BPaMZ in the 
treatment of drug-susceptible tuberculosis is isoniazid 
monoresistance in active tuberculosis: the global 
prevalence is estimated to be approximately 8% of all new 
cases, and use of HRZE leads to worse outcomes when 
treating isoniazid mono-resistant strains than when 
treating fully susceptible strains.23 However, treatment 
outcomes involving drug-susceptible tuber culosis and 
those with resistant organisms need to be assessed in 
larger prospective trials.
The efficacy of BPaMZ was similar in HIV-positive and 
HIV-negative patients, but there was a reduction in 
bactericidal activity for patients with pyrazinamide-
resistant rifampicin-resistant tuberculosis (although this 
decreased bactericidal activity was still greater than that of 
HRZE). HIV-positive patients with active tuberculosis are 
more likely to have treatment failure in cases of both drug-
susceptible and drug-resistant tuberculosis, although this 
is mitigated to a large degree by antiretroviral therapy,24 or 
to have poor adherence to treatment, often due to drug 
toxicities.25,26 
In light of these findings, the preserved bactericidal 
activity with BPaMZ in HIV-positive patients is 
encouraging but the numbers were small and it is not 
possible to draw firm conclusions. Pyrazinamide 
resistance is also associated with worse outcomes 
in rifampicin-resistant tuberculosis treat ment,27 and 
approximately 60% of rifampicin-resistant tuberculosis 
cases are thought to be pyrazinamide resistant.28 If this 
sustained bactericidal activity in patients with both HIV 
and pyrazinamide-resis tant rifampicin-resistant tuber-
culosis results in improved long-term treatment out-
comes, then BPaMZ could improve treatment success 
among these patients.
The simplified dosing schedule of 200 mg daily for 
bedaquiline to treat drug-susceptible tuberculosis 
showed similar efficacy to the BloadPaZ regimen using 
the estab lished dosing approach, and there are impli-
cations from this for other bedaquiline-containing 
rifampicin-resistant tuberculosis treatment regimens 
used elsewhere. 
A daily dosing schedule could help to reduce the 
burden on both patients and health-care providers, and 
it has been shown that simplified dosing schedules are 
associated with improved adherence to treatment in 
other conditions.29,30 The daily-dosing approach was 
used to treat patients with drug-susceptible tuberculosis 
and those with rifam picin-resistant tuberculosis in this 
study, performing better than HRZE against drug-
susceptible tuberculosis in both the primary and 
secondary efficacy endpoints. Additionally, there was no 
indication of a safety signal with daily bedaquiline 
dosing and the addition of moxifloxacin was not 
associated with higher frequency of QT prolongation on 
ECG monitoring, and this finding is in keeping with 
other data relating to the low incidence of cardiac 
arrhythmias associated with bedaquiline use in the 
field.31
Over 8 weeks of treatment, the safety profile of BPaMZ 
was similar to that of HRZE, whereas the incidence 
of peak liver enzyme elevations was higher among 
patients with drug-susceptible tuberculosis treated with 
bedaquiline-containing and pretomanid-containing 
drugs. The proportion of HIV-positive patients, the 
baseline weight, and treatment adherence was similar 
across all the treatment groups in the study. There was 
also no geographical association with toxicity and cases 
were spread across the trial sites. Additionally, the only 
death from liver failure occurred in the HRZE group.
Pharmacokinetic and pharmacodynamic data relating to 
the trial is to be published in a separate paper, and a larger 
phase 3 study is required to accurately characterise the 
safety profile of these experimental regimens. The current 
therapy for treating pulmonary tuberculosis is toxic, with 
clinically significant hepatotoxicity in 5–30% of patients,32 
and part of the global effort to move beyond HRZE should 
be motivated by the need for alternative therapies with 
fewer side-effects.
This study has several limitations: first, the 8-week 
bactericidal activity of a drug regimen is not always a 
reliable indicator of a regimen’s ability to improve treat-
ment outcomes or shorten treatment duration. We accept 
that there are limitations to the current approach in 
tuberculosis trials of using early bactericidal activity as a 
means of predicting long-term treatment outcomes and 
are also aware of other methodological approaches that 
have been proposed (including modelling approaches and 
adaptive trial designs). However, the 8-week study remains 
a broadly accepted (although imperfect) means of assessing 
the potential of experi mental regimens as candidates for 
phase 3 trials. 
We would ultimately argue that phase 2 studies still 
have a place in the development of tuberculosis treat-
ment regimens and that culture conversion in the first 
2 months of treatment is associated with outcomes in 
phase 3 studies but that these predictions can be 
imprecise. The fluoroquinolone trials were latterly 
acknow ledged as having wide CIs around the point 
estimates in phase 2 studies, and the phase 3 outcomes 
are in the lower end of these intervals. It could be argued 
that the method presented in this paper still has a place 
in tuberculosis drug development, but previous studies 
have involved regimens that were insufficient and our 
understanding of how to interpret the results was less 
robust than it is now.
Additionally, this trial does not address the issue of what 
is an appropriate continuation phase and the continuation 
phase in the previous fluoroquinolone trials might have 
been inadequate. Furthermore, this study involves 
regimens that contain several experimental drugs; 
therefore, there is more equipoise over the regimens’ 
ability to shorten tuberculosis treatment. Also, the overall 
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small numbers of HIV-positive and female patients might 
reduce the generalisability of these findings.
Finally, caution needs to be applied when comparing the 
results from a randomly assigned group of patients with 
drug-susceptible tuberculosis to those seen among the 
rifampicin-resistant tuberculosis patients, who were not 
randomly assigned to the treatment. The rifampicin-resis-
tant tuberculosis group of the trial was initially included as 
an exploratory arm to use the trial facilities as the setting to 
gather efficacy and safety data relating to the BPaMZ 
regimen. The presumed susceptibility to bedaq uiline and 
pretomanid, with molecular testing for pyrazinamide and 
fluoroquinolone susceptibility, provided the scientific and 
ethical justification for enrolling these patients in an 
additional group without randomisation. 
The comparisons across the treatment groups were 
also considered reasonable in this case because the 
patients recruited into the study were all enrolled on the 
basis of the same inclusion and exclusion criteria, with 
no significant differences seen in the baseline charac-
teristics of the patients recruited, although this does not 
mean that there were not differences. 
One issue that should be highlighted is the higher 
proportion of patients with rifampicin-resistant tuber-
culosis receiving ART at baseline than patients with drug-
susceptible tuberculosis (64% vs 0–10%) and, as mentioned 
previously, ART can improve treatment outcomes among 
HIV-positive patients. Furthermore, if all of the treatment 
groups are considered to be susceptible to the regimen 
(noting the pyrazinamide resistance of the rifampicin-
resistant tuberculosis) then the rationale was applied that 
comparisons were not only between similar patients but 
also between similar infections.
In conclusion, the BPaMZ regimen showed greater 
8 week bactericidal activity against rifampicin-resistant 
tuber culosis than did HRZE against drug-susceptible 
tuberculosis in this phase 2b study. This all-oral regimen 
could overcome some of the shortcomings of existing 
rifampicin-resistant tuberculosis therapy and also 
possibly shorten treatment of drug-susceptible tuber-
culosis. The data presented here suggest that further 
investigation of treatment outcomes and the safety 
profile of BPaMZ is merited in both rifampicin-resistant 
tuberculosis and drug-susceptible tuberculosis, as is the 
further study of the efficacy and safety of the daily dosing 
schedule of bedaquiline in other regimens. These 
findings are a step forward in the development of the 
simple, efficacious, and safe treatment options needed in 
the treatment of drug-susceptible tuberculosis and 
rifampicin-resistant tuber culosis to meet the ambitious 
goals of WHO’s End TB strategy.
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